Laflunimus
Cat. No.: IBDI-436262
Laflunimus (HR325) is an immunosuppressive agent and an analogue of the Leflunomide-active metabolite A77 1726. Laflunimus is an orally active inhibitor of dihydroorotate dehydrogenase (DHODH). Laflunimus suppresses immunoglobulin (Ig) secretion, with IC50 values of 2.5 and 2 µM for IgM and IgG, respectively. Laflunimus also is a prostaglandin endoperoxide H synthase (PGHS) -1 and -2 inhibitor.
Size (Solid + Solvent): 10 mM * 1 mL ready for reconstitution
Online Inquiry
Product Details
| Target |
Dihydroorotate Dehydrogenase | DNA/RNA Synthesis | Prostaglandin Receptor |
| Molecular Weight |
310.27 |
| Appearance |
Solid |
| Synonyms |
HR325 |
| Purity |
99.76% |
Storage & Handling
| Shipping |
Room temperature in continental US. May vary elsewhere. |
| Storage |
Powder: -20°C/3 years; 4°C/2 years
In solvent: -80°C/6 months; -20°C/1 month |
| Regulatory Status |
This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. |
! For research use only, not intended for any clinical use.
